癌症患者对新冠疫苗接种的体液免疫反应——ANRS0001S COV-POPART研究结果
Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART study.
作者信息
Luong Nguyen Liem Binh, Magloire Lyvia, François Alexis, Billard David, Priou Frank, Arrondeau Jennifer, Linassier Claude, Ben Ghezala Ines, Gross-Goupil Marine, Charles Julie, Dohollou Nadine, Vanhems Philippe, Cracowski Claire, Leroi Anne Marie, Lainé Fabrice, Galtier Florence, Barthelemy Karine, Priet Stéphane, Gharib Mariam, Chalouni Mathieu, Barquin Aude, Loubet Paul, de Lamballerie Xavier, Launay Odile, Wittkop Linda, Blay Jean-Yves, Spano Jean-Philippe
机构信息
INSERM, F-CRIN, Reseau Innovative Clinical Research in Vaccinology (IREIVAC), Paris, France; Centre d'Investigation Clinique Cochin Pasteur, Paris, France; Université de Paris, Paris, France.
Univ. Bordeaux, INSERM, MART, UMS 54, F-33000 Bordeaux, France.
出版信息
Vaccine. 2025 Sep 17;63:127633. doi: 10.1016/j.vaccine.2025.127633. Epub 2025 Aug 22.
BACKGROUND
Patients with cancer, whose immune responses to vaccines are commonly weaker than those of the general population, are recommended a booster dose after two initial doses of Covid-19 vaccine. Our objective was to compare the humoral immunogenicity of Covid-19 vaccines in patients with cancer compared to healthy adults (control group) after primary vaccine series and after a booster dose.
METHODS
We included participants aged ≤75 and vaccinated with two doses in the primary vaccine series and a booster, from the French national prospective Covid-19 vaccine cohort study (ANRS0001S COV-POPART) and excluded those with SARS-CoV-2 infection. Percentage of responders, geometric mean titers (GMT) of anti-SARS-CoV-2 IgG antibodies (ELISA) and specific neutralizing antibodies against original strain, Delta and Omicron variants of concern, were estimated one month after the primary vaccine series, then one month and six months after a booster dose.
RESULTS
We included 183 patients with cancer and 1173 controls. The most frequent cancers were breast (37.2 %) and lung cancer (17.5 %). Patients with cancer were older and had lower anti-Spike IgG levels after the primary vaccine series (GMT = 132.4 vs 332.7 BAU/mL, P < 0.0001), but they developed similar response at one month (GMT = 2146.1 vs 1841.3 BAU/mL], P = 0.16) and six months after booster (602.0 vs 574.4 BAU/mL, P = 0.80). Neutralizing antibodies levels confirmed these results.
CONCLUSION
Patients with cancer have comparable response rates to controls one month and six months after a booster dose. Our results support the benefit of a booster dose in patients with cancer.
背景
癌症患者对疫苗的免疫反应通常比普通人群弱，建议在接种两剂新冠疫苗后再接种一剂加强针。我们的目的是比较癌症患者与健康成年人（对照组）在完成基础疫苗系列接种后以及接种加强针后的新冠疫苗体液免疫原性。
方法
我们纳入了法国全国性前瞻性新冠疫苗队列研究（ANRS0001S COV-POPART）中年龄≤75岁、接种了两剂基础疫苗系列和一剂加强针的参与者，并排除了感染过新冠病毒的患者。在完成基础疫苗系列接种后1个月，然后在接种加强针后1个月和6个月，评估应答者百分比、抗SARS-CoV-2 IgG抗体的几何平均滴度（GMT）（酶联免疫吸附测定）以及针对原始毒株、德尔塔和奥密克戎变异株的特异性中和抗体。
结果
我们纳入了183例癌症患者和1173例对照。最常见的癌症是乳腺癌（37.2%）和肺癌（17.5%）。癌症患者年龄较大，在完成基础疫苗系列接种后抗刺突蛋白IgG水平较低（GMT = 132.4 vs 332.7 BAU/mL，P < 0.0001），但他们在接种加强针后1个月（GMT = 2146.1 vs 1841.3 BAU/mL，P = 0.16）和6个月（602.0 vs 574.4 BAU/mL，P = 0.80）时产生了相似的反应。中和抗体水平证实了这些结果。
结论
癌症患者在接种加强针后1个月和6个月的反应率与对照组相当。我们的结果支持癌症患者接种加强针的益处。
Zotero 插件